If this is the case then it is very plausible to speculate that most of existing and ongoing immunotherapies, including anti-CTLA4 and anti-CD20 will have limited therapeutic effect on mismatch repair proficient CRC patients. This evidence concerns the gene CTLA4 and colorectal carcinoma.